Keros Therapeutics Doses First Patient In Mid-Stage Rinvatercept Trial For Duchenne Muscular Dystrophy
The clinical-stage biotech expects initial safety and efficacy data from the open-label DMD study in the first half of 2027.
Keros Therapeutics dosed the first patient in a mid-stage trial of rinvatercept for Duchenne muscular dystrophy, the company announced Monday in an 8-K filed with the SEC. The milestone advances Keros' lead drug candidate into clinical testing for a second serious neuromuscular disease, with an initial data readout penciled in for the first half of 2027.
What The Trial Is Testing
The mid-stage study is an open-label, multi-cohort trial enrolling both late-ambulatory and early non-ambulatory DMD patients. Its primary goal is to assess rinvatercept's safety and tolerability in those two groups, according to the press release. Secondary objectives cover how the drug moves through the body, whether patients develop antibodies against it, changes in body composition, and functional improvements spanning skeletal muscle, motor, cardiac, and pulmonary measures.
Rinvatercept works by blocking myostatin and activin A — proteins that suppress muscle and bone growth. By inhibiting those signals, the drug is designed to promote skeletal muscle regeneration, increase muscle size and strength, reduce fibrosis and inflammation, cut fat accumulation, and improve bone health. Keros describes it as a ligand trap built from modified binding domains of two activin receptors fused to a human antibody's Fc domain.
Gina O'Grady, a pediatric neurologist at Starship Children's Hospital, said in the announcement that DMD "continues to place a significant burden on patients and their families, and the need for additional options remains high" despite advances in treatment. She added that rinvatercept's mechanism, as established in preclinical work, "provides a compelling rationale for clinical evaluation in DMD" across both ambulatory and non-ambulatory patients.
Rinvatercept's Broader Role In Keros' Pipeline
DMD is not the only disease Keros is pursuing with rinvatercept. The company is also developing the drug for amyotrophic lateral sclerosis, making it the centerpiece of what Keros calls its neuromuscular development strategy. Jasbir S. Seehra, Ph.D., Keros' president and chief executive officer, said in the announcement that the company looks "forward to generating clinical data to inform its potential to treat patients with DMD."
Keros' other advanced candidate, elritercept, targets blood disorders — specifically anemia and low platelet counts in patients with myelodysplastic syndromes and myelofibrosis. That program is partnered with Takeda under a global licensing arrangement that makes Keros eligible for more than $1.1 billion in potential development, commercial, and sales milestones, according to a separate Keros announcement.
What To Watch
KROS shares edged down about 0.5% to $11.20 in Friday trading, according to market data.
The next major catalyst for the rinvatercept DMD program is the initial data readout, which Keros expects to deliver in the first half of 2027. That report will cover early safety and tolerability findings — the trial's primary endpoint — along with any preliminary signals on pharmacokinetics and functional measures across the ambulatory and non-ambulatory cohorts. Enrollment progress across those two patient groups is also worth tracking in the interim.
The first-half 2027 data readout will be the first clinical test of whether rinvatercept's preclinical muscle-biology rationale translates to DMD patients.
Sources
- 8-K Filing — Keros Therapeutics, Inc. (KROS) — SEC EDGAR
- Exhibit exhibit99192826pr.htm — Keros Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Keros Therapeutics to Receive Additional Development — globenewswire.com
- Keros Therapeutics Announces the First Patient Dosing in — globenewswire.com
